Related references
Note: Only part of the references are listed.Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study
Philipp Eisele et al.
JOURNAL OF NEUROIMAGING (2019)
Grey matter atrophy is associated with disability increase in natalizumab-treated patients
Ethel Ciampi et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Brain MRI atrophy quantification in MS From methods to clinical application
Maria A. Rocca et al.
NEUROLOGY (2017)
Grey matter atrophy is associated with disability increase in natalizumab-treated patients
Ethel Ciampi et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis
E. Fisher et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis
E. Fisher et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis
Raed Alroughani et al.
BMC NEUROLOGY (2016)
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine
Robert Zivadinov et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - NO
Frederik Barkhof
MULTIPLE SCLEROSIS JOURNAL (2016)
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine
Robert Zivadinov et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Brain atrophy measurements should be used to guide therapy monitoring in MS - NO
Frederik Barkhof
MULTIPLE SCLEROSIS JOURNAL (2016)
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
Sheena L. Dupuy et al.
NEUROLOGY AND THERAPY (2016)
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
David H. Miller et al.
NEUROLOGY (2015)
The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
Georgios Tsivgoulis et al.
PLOS ONE (2015)
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Brain atrophy and lesion load predict long term disability in multiple sclerosis
Veronica Popescu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
Angela Vidal-Jordana et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
A Bayesian model of shape and appearance for subcortical brain segmentation
Brian Patenaude et al.
NEUROIMAGE (2011)
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
N. De Stefano et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
R. Zivadinov et al.
NEUROLOGY (2008)
The measurement and clinical relevance of brain atrophy in multiple sclerosis
RA Bermel et al.
LANCET NEUROLOGY (2006)
Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis
R Bakshi et al.
JOURNAL OF NEUROIMAGING (2005)
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis
SM Smith et al.
NEUROIMAGE (2002)
The clinico-radiological paradox in multiple sclerosis revisited
F Barkhof
CURRENT OPINION IN NEUROLOGY (2002)
Normalized accurate measurement of longitudinal brain change
SM Smith et al.
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2001)
Brain atrophy in relapsing multiple sclerosis:: relationship to relapses, EDSS, and treatment with interferon β-Ia
RA Rudick et al.
MULTIPLE SCLEROSIS (2000)
Share Paper
